• 1
    Paige CF, Abbott JA, Elvinger F, et al. Prevalence of cardiomyopathy in apparently healthy cats. J Am Vet Med Assoc 2009;234:1398403.
  • 2
    Fox PR. Spontaneous animal models. In: Marcus FI, Nava A, Thiene G eds. Arrhythmogenic RV Cardiomyopathy/Dysplasia Recent Advances. Italia: Springer-Verlag; 2007:6978.
  • 3
    Fox PR, Liu SK, Maron BJ. Echocardiographic assessment of spontaneously occurring feline hypertrophic cardiomyopathy. An animal model of human disease. Circulation 1995;92:26452651.
  • 4
    Fox PR. Hypertrophic cardiomyopathy. Clinical and pathologic correlates. J Vet Cardiol 2003;5:3945.
  • 5
    Mandell DC. Respiratory distress in cats. In: King LG, ed. Respiratory Disease in Dogs and Cats. St Louis: WB Saunders; 2004:1217.
  • 6
    Schober KE, Maerz I, Ludewig E, et al. Diagnostic accuracy of electrocardiography and thoracic radiography in the assessment of left atrial size in cats: Comparison with transthoracic 2 dimensional echocardiography. J Vet Intern Med 2007;21:709718.
  • 7
    Wood MJ, Picard MH. Utility of echocardiography in the evaluation of individuals with cardiomyopathy. Heart 2004;90:707712.
  • 8
    Charron P, Forissier JF, Amara ME, et al. Accuracy of European diagnostic criteria for familial hypertrophic cardiomyopathy in a genotyped population. Int J Cardiol 2003;90:3338.
  • 9
    Schober KE, Fuentes VL, Bonagura JD. Comparison between invasive hemodynamic measurements and noninvasive assessment of left ventricular diastolic function by use of Doppler echocardiography in healthy anesthetized cats. Am J Vet Res 2003;64:93103.
  • 10
    2007 U.S. Pet Ownership & Demographics Sourcebook. Schaumburg, IL: American Veterinary Medical Association. 2007.
  • 11
    Nakagawa O, Ogawa Y, Itoh H, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an ‘‘emergency’’ cardiac hormone against ventricular overload. J Clin Invest 1995;3:12801287.
  • 12
    Maeda K, Tsutamoto T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825832.
  • 13
    Braunwald E. Biomarkers in heart failure. N Engl J Med 2008;358:21482159.
  • 14
    Fox PR, Oyama MA, Reynolds C et al. Utility of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) to distinguish between congestive heart failure and non-cardiac causes of acute dyspnea in cats. J Vet Cardiol 2009;11(Suppl. 1):S51S61. Epub April 24, 2009.
  • 15
    Connolly DJ, Soares Magalhaes RJ, Syme HM, et al. Circulating natriuretic peptides in cats with heart disease. J Vet Intern Med 2008;22:96105.
  • 16
    Oyama MA, Rush JE, Rozanski EA, et al. Assessment of serum N-terminal pro-B-type natriuretic peptide concentration for differentiation of congestive heart failure from primary respiratory tract disease as the cause of respiratory signs in dogs. J Am Vet Med Assoc 2009;235:13191325.
  • 17
    Betti I, Castelli G, Barchielli A, et al. The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study. J Card Fail 2009;15:377384.
  • 18
    Wang TJ, Levy D, Benjamin EJ, et al. The epidemiology of “asymptomatic” left ventricular systolic dysfunction: implications for screening. Ann Intern Med 2003;138:907916.
  • 19
    Heidenreich PA, Gubens MA, Fonarow GC, et al. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 2004;43:10191026.
  • 20
    Hsu A, Kittleson MD, Paling A. Investigation into the use of plasma NT-proBNP concentration to screen for feline hypertrophic cardiomyopathy. J Vet Cardiol 2009;11(Suppl. 1):S6370. Epub April 22, 2009.
  • 21
    Biondo AW, Ehrhart EJ, Sisson DD, et al. Immunohistochemistry of atrial and brain natriuretic peptides in control cats and cats with hypertrophic cardiomyopathy. Vet Pathol 2003;40:501506.
  • 22
    MacDonald KA, Kittleson ME, Larson RF, et al. The effect of ramipril on left ventricular mass, myocardial fibrosis, diastolic function, and plasma neurohormones in Maine Coon cats with familial hypertrophic cardiomyopathy without heart failure. J Vet Intern Med 2006;20:10931105.
  • 23
    Wess G, Daisenberger P, Mahling M, et al. Utility of measuring plasma N-terminal pro-brain natriuretic peptide in detecting hypertrophic cardiomyopathy and differentiating grades of severity in cats. Vet Clin Pathol 2011;40:237244.
  • 24
    Thomas WP, Gaber CE, Jacobs GJ, et al. Recommendations for standards in transthoracic two-dimensional echocardiography in the dog and cat. Echocardiography Committee of the Specialty of Cardiology, American College of Veterinary Internal Medicine. J Vet Intern Med 1993;7:247252.
  • 25
    Schober KE, Fuentes VL, Bonagura JD. Comparison between invasive hemodynamic measurements and noninvasive assessment of left ventricular diastolic function by use of Doppler echocardiography in healthy anesthetized cats. Am J Vet Res 2003;64:93103.
  • 26
    Oyama MA, Sisson DD, Bulmer BJ, et al. Echocardiographic estimation of mean left atrial pressure in a canine model of acute mitral valve insufficiency. J Vet Intern Med 2004;18:667672.
  • 27
    Fox PR. Feline cardiomyopathies. In: Fox PR, Sisson DD, Moïse NS, eds. Textbook of Canine and Feline Cardiology. Principles and Clinical Practice, 2nd ed. Philadelphia, PA: WB Saunders Co; 1999:621678.
  • 28
    Fox PR. Endomyocardial fibrosis and restrictive cardiomyopathy: pathologic and clinical features. J Vet Cardiol 2004;6:2531.
  • 29
    Arteaga E, Araujo AQ, Buck B, et al. Plasma amino-terminal pro–B-type natriuretic peptide quantification in hypertrophic cardiomyopathy. Am Heart J 2005;150:12281232.
  • 30
    Kim SW, Park SW, Lim SH, et al. Amount of left ventricular hypertrophy determines the plasma N-terminal pro-brain natriuretic peptide level in patients with hypertrophic cardiomyopathy and normal left ventricular ejection fraction. Clin Cardiol 2006;4:155160.
  • 31
    Wess G, Schinner C, Weber K, et al. Association of A31P and A74T polymorphisms in the myosin binding protein C3 gene and hypertrophic cardiomyopathy in Maine Coon and other breed cats. J Vet Intern Med 2010;24:527532.
  • 32
    Troughton RW, Richards MR. B-type natriuretic peptides and echocardiographic measures of cardiac structure and function. J Am Coll Cardiol 2009;2:216225.